The tariff war between US and China has eased, but with the Iran conflict and an erratic Trump, uncertainty will continues unabated. Energy prices have gone ballistic, with gas prices doubling in Europe and has hit the cyclical stocks hard. KBC macro-econimists have hiked the inflation expectation for 2026 from 1.9% to 3.3%. While the macro-economic impact has been limited so far, a prolonged uncertain situation will result in economic damage. We continue our defensive stance in our Benelux Dyna...
ONWARD Medical Publishes Convocation of the 2026 Annual General Meeting of Shareholders and Proposed Resolutions EINDHOVEN, the Netherlands, April 01, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today convened the 2026 Annual General Meeting of Shareholders (AGM), which will be held in Amsterdam, the Netherlands, on May 13, 2026. The resolutions proposed by the Board, to be su...
Onward's FY25 update shows solid commercial execution, although results came in slightly below expectations. The company sold 117 ARC-EX devices (KBCSe: 128) and generated € 5.4m in revenue (VA CSS: € 6.7m). However, we note that the ARC-EX system is now available in over 80 US rehabilitation centers (around 25% of specialized centers) representing solid market penetration for its first year. The company expects an acceleration of ARC-EX uptake in 2026 thanks to the home use label with particula...
ONWARD Medical Reports Full Year 2025 Financial and Operating Results, Highlighting Strong US Commercial Performance and Major Pipeline Milestones THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, March 31, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces i...
Barco continues to face weak demand in Healthcare and Enterprise, while we believe that Entertainment momentum is likely to fade as tariffs, a weak USD and fallout from the Iran conflict soften performance. The sizeable VerVent Audio acquisition, prioritised over buybacks, limits capital allocation flexibility. Although we believe the valuation at 11x PER 2027F is undemanding, the lack of a sustainable return to growth caps near-term upside. We reduce our target price to €10 per share (from €16)...
ONWARD Medical Schedules Webcast to Report Full-Year 2025 Financial Results and Provide Business Update EINDHOVEN, the Netherlands, March 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announces that it will report Full-Year 2025 Financial Results and host a webcast to provide a comprehensive business update on March 31, 2026. Presented by CEO Dave Marver, the webcast will be h...
Ekopak's FY25 results, while showing tighter cost discipline, were overshadowed by the withdrawal of the EPICO infrastructure fund from the Waterkracht project—creating the risk of significant operational delays or even full project loss. Although a new partnership with an infrastructure fund is intended to finance large WaaS installations through off balance sheet SPVs, the first joint project award is yet to be announced. With Waterkracht removed from our numbers, valuation remains demanding, ...
We reiterate our BUY rating and increase our target price from €13.50 to €14.50, following Recticel's FY25 results. We remain convinced by Recticel's ability to continue to improve its profitability, even without any support from the current macroeconomic environment, thanks to its renewed focus on high value-added products, as well as its disciplined M&A approach. This should lead to a material improvement in Recticel's product mix, whilst its above-market profitability growth should warrant a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.